Mostly Sunny, Chance of Showers
In the last issue, we wrote about the myriad crosscurrents that were still being seen—while the major indexes looked good, the day-to-day rotation was wild among sectors and themes, with news-driven moves the norm for a few weeks. But also...
Read More
The Big Idea
For the last nine months the world has been mostly focused on the Covid-19 pandemic and the related importance of testing, treatments and, hopefully, an effective cure in the form of vaccinations.
But while the pandemic has taken center stage in 2020 remains...
Read More
Other than price changes not much has happened with our stocks since I wrote last week. With our offices closed tomorrow and Friday we’ll all be taking a short break before gearing up for the last month of the year.
Read More
Remain optimistic but pick your stocks carefully. The overall market is in good shape, and there’s definitely more good than bad among individual stocks, though it’s also tricky, with plenty of rotation and news-driven moves.
Read More
Wild—but Positive—Action
The healthiest market environment is generally one where most participants are rowing in the same direction—the vast majority of stocks and sectors glide higher (with the occasional pullback or shakeout, of course) as investor perception of the future steadily improves. Even if broad...
Read More
After an insane couple of weeks this one has felt relatively calm. There is still plenty of market-moving news around the election, vaccines, the pandemic’s frightening trajectory, etc. but I think we’ve all become somewhat accustomed enough to alarming headlines – within a range...
Read More
Stock Name
Market Cap
Price
Investment Type
Avantor (AVTR)
$15.8 billion
27.46
Growth – MedTech
Berkeley Lights (BLI)
$5.5 billion
86.15
Rapid Growth - MedTech
e.l.f. Beauty (ELF)
$1.1 billion
21.67
Growth – Personal Care
Farfetch Limited (FTCH)
$15.2 billion
44.56
Rapid Growth - Ecommerce
Kornit Digital (KRNT)
$3.2 billion
79.06
Rapid Growth – Textile Printing
Preparing for the Next Phase of the Pandemic
The current investing climate one...
Read More
This portfolio stock reported Q3 results yesterday that came in ahead of expectations.
Read More
Stay cautious for now as we wait to see whether growth stocks can find their footing (which they’ve done for a couple days in a row now).
Read More
The market is working its way through significant developments on many fronts – U.S. presidential race, raging pandemic, positive vaccine developments – and information overload is causing some intense action in individual stocks.
Read More
Tyler reports on three stocks in the portfolio.
Read More
The market continues to react to the good news on the vaccine front, but growth stocks continue to suffer. Today we’re taking another incremental step to wind down some of our exposure.
Read More
The U.S. and the world has cleared two of the biggest hurdles of uncertainty out there. I am, of course, talking about the U.S. presidential election and the Pfizer and BioNTech vaccine news.
Read More
Believe What You See
There are usually a couple of times each year where the market really messes with people, catching the vast majority of investors off-guard. (Remember the old saw: The market does what it has to do to fool the most investors One...
Read More
The Big Idea
The cell and gene therapy market is one of the fastest growing and most exciting areas of medicine. Analysts see it growing at an average clip of 30% through 2025, powered by expected approvals of more therapies over the next five are...
Read More
Tyler recommends selling one stock and gives earnings updates on five more.
Read More
A day like yesterday can make investors feel like there’s little reason to hang around in this market.
Read More
Be cautious. Growth stocks have been under pressure since early/mid-October, and our Cabot Tides buy signal has fallen by the wayside.
Read More
We're selling one stock and buying another half on two others.
Read More
Riding the Bucking Bronco
Investing in general, and growth stock investing in particular, tends to be very streaky—while many would love for a steady, low-stress increase in their portfolios, that’s not how the world usually works. Instead you get periods of time when the gushes...
Read More